The drugmaker already filed for approval for the age group in Canada and Europe.
In a study of nearly 2,500 kids aged 12 to 17, the vaccine was 100 percent effective against COVID-19. Moderna said it was also 93 percent effective against mild disease 14 days after a single dose.
No significant safety concerns were discovered in the trial, and the most common side effect was injection site pain.
Read Moderna’s full news release here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
